TRIL - トリリウム・セラピュ―ティクス (Trillium Therapeutics Inc.)

TRILのニュース

   Trillium Therapeutics Sees Unusually Large Options Volume (NASDAQ:TRIL)  2020/11/18 17:03:41 Transcript Daily
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) saw some unusual options trading activity on Tuesday. Stock investors purchased 3,400 put options on the company. This is an increase of 1,317% compared to the typical volume of 240 put options. Hedge funds and other institutional investors have recently made changes to their positions in the stock. VR Adviser […]
   H.C. Wainwright Stick to Their Buy Rating for Trillium Therapeutics  2020/11/18 11:15:44 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Trillium Therapeutics
   JonesTrading Stick to Their Buy Rating for Trillium Therapeutics  2020/11/17 14:26:48 Investing.com
JonesTrading Stick to Their Buy Rating for Trillium Therapeutics
   Trillium Therapeutics reports 9M results (NASDAQ:TRIL)  2020/11/16 12:12:16 Seeking Alpha
Trillium Therapeutics (NASDAQ:TRIL): 9M GAAP EPS of -$2.19. Revenue of $0.11M (-35.3% Y/Y) Press Release
   Trillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical Officer  2020/11/02 21:15:00 GlobeNewswire
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage…
   2 Top Growth Stocks to Buy Now  2020/10/25 14:00:41 The Motley Fool Canada
Trillium Therapeutics (TSX:TRIL)(NASDAQ:TRIL) and Docebo (TSX:DCBO) are two top-performing growth stocks that will help you to earn superior returns. The post 2 Top Growth Stocks to Buy Now appeared first on The Motley Fool Canada .
   Trillium Therapeutics (NASDAQ:TRIL) Trading Down 5.4%  2020/10/22 10:00:06 Stock Observer
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) traded down 5.4% during trading on Tuesday . The company traded as low as $13.55 and last traded at $13.58. 1,447,964 shares were traded during mid-day trading, a decline of 52% from the average session volume of 3,041,178 shares. The stock had previously closed at $14.35. A number of analysts […]
   Trillium Therapeutics (NASDAQ:TRIL) Shares Down 5.4%  2020/10/20 18:58:47 US Banking News
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR)’s share price was down 5.4% during mid-day trading on Tuesday . The stock traded as low as $13.55 and last traded at $13.58. Approximately 1,447,964 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 3,041,178 shares. The stock had previously closed at $14.35. […]
   Zacks: Brokerages Anticipate Trillium Therapeutics Inc. (NASDAQ:TRIL) to Post -$0.14 EPS  2020/10/19 17:16:42 Transcript Daily
Equities research analysts expect that Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) will announce ($0.14) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Trillium Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.09). Trillium Therapeutics posted earnings per […]
   2 Under-the-Radar Growth Stocks to Buy in 2020  2020/10/08 17:15:02 The Motley Fool Canada
Growth investors should watch out for the Trillium Therapeutics stock and SunOpta stock. Both companies are flying under the radar and are capable of delivering massive rewards in 2020 and beyond. The post 2 Under-the-Radar Growth Stocks to Buy in 2020 appeared first on The Motley Fool Canada .
   The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO  2020/09/15 11:55:39 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Stoke Therapeutics Inc (NASDAQ: STOK ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AEterna Zentaris Inc. (NASDAQ: AEZS ) BELLUS Health Inc (NASDAQ: BLU ) PainReform Ltd (NASDAQ: PRFX ) Predictive Oncology Inc (NASDAQ: POAI ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Marinus Reports Positive Late-Stage Readout In Epilepsy Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) announced positive top-line results from its registrational Phase 3 clinical trial, dubbed Marigold, evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder, a rare, genetic epilepsy with refractory seizures.
   The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review  2020/09/11 12:05:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reacted to results for the half-year) Burning Rock Biotech Ltd (NASDAQ: BNR ) Evofem Biosciences Inc (NASDAQ: EVFM ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Pandion Therapeutics Inc (NASDAQ: PAND ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) ( reacted to a negative late-stage clinical readout for investigational migraine drug) Stocks In Focus Roche Presents Positive Long-Term Data For Multiple Sclerosis Drug Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) announced …
   Trillium Therapeutics Up 40% On Data From Lead Cancer Candidates, Pfizer Investment  2020/09/09 17:08:08 Benzinga
Shares of clinical stage immuno-oncology company Trillium Therapeutics Inc's (NASDAQ: TRIL ) are trading higher on encouraging updated data from its ongoing lead cancer candidates TTI-622 and TTI-621 that was released after hours Tuesday. What Happened: Preliminary data from the TTI-621 (SIRPa-IgG1 Fc fusion protein) four-part Phase 1 trial in patients with advanced relapsed or refractory hematologic malignancies showed that weekly infusions of up to 1.4 mg/kg are well-tolerated without dose-limiting thrombocytopenia. Platelet decreases occurred on dosing days and recovered in two to four days. The antitumor activity in the 1mg/kg dose includes one partial response and one complete response in six evaluable patients. Two of those patients were bridged to allogeneic transplantation. The enrollment in the 2mg/kg cohort is underway. Preliminary data from … Full story available on Benzinga.com
   Mid-Day Market Update: Dow Jumps Over 500 Points; Trillium Therapeutics Shares Spike Higher  2020/09/09 12:04:00 Benzinga
Midway through trading Wednesday, the Dow traded up 1.90% to 28,024.77 while the NASDAQ rose 2.69% to 11,139.51. The S&P also rose, gaining 2.18% to …
   Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level  2020/07/30 11:00:00 GlobeNewswire
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage…

calendar